| Major Depressive Disorder
Fetzima vs Viibyrd
Side-by-side clinical, coverage, and cost comparison for major depressive disorder.Deep comparison between: Fetzima vs Viibryd with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsViibryd has a higher rate of injection site reactions vs Fetzima based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Viibryd but not Fetzima, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fetzima
Viibryd
At A Glance
Oral
Once daily
SNRI
Oral
Daily
SSRI / 5-HT1A partial agonist
Indications
- Major Depressive Disorder
- Major Depressive Disorder
Dosing
Major Depressive Disorder Initiate at 20 mg once daily for 2 days, then increase to 40 mg once daily; may increase in 40 mg increments at intervals of 2 or more days; max 120 mg once daily, oral, with or without food.
Renal Impairment Severe (CrCl 15-29 mL/min): max 40 mg once daily; moderate (CrCl 30-59 mL/min): max 80 mg once daily; ESRD: not recommended.
Major Depressive Disorder Start at 10 mg once daily with food for 7 days, then increase to 20 mg once daily; may increase up to 40 mg once daily after a minimum of 7 days between dosage increases; target dose is 20-40 mg once daily with food.
Contraindications
- Hypersensitivity to levomilnacipran, milnacipran HCl, or any excipient in the formulation
- Concomitant use with MAOIs intended to treat psychiatric disorders, or within 7 days of stopping FETZIMA
- Use of FETZIMA within 14 days of stopping an MAOI intended to treat psychiatric disorders
- Concomitant use with linezolid or intravenous methylene blue
- Concomitant use or within 14 days of stopping MAOIs, including linezolid or intravenous methylene blue, due to increased risk of serotonin syndrome
Adverse Reactions
Most common (>=5%) Nausea, constipation, hyperhidrosis, heart rate increased, erectile dysfunction, ejaculation disorder, tachycardia, vomiting, palpitations
Serious Suicidal thoughts and behaviors, serotonin syndrome, elevated blood pressure, elevated heart rate, increased risk of bleeding, angle closure glaucoma, urinary hesitation or retention, activation of mania/hypomania, seizure, discontinuation syndrome, hyponatremia, sexual dysfunction
Postmarketing Takotsubo cardiomyopathy, anosmia, hyposmia
Most common (>=5%) Diarrhea, nausea, vomiting, insomnia
Serious Suicidal thoughts and behaviors, serotonin syndrome, increased risk of bleeding, activation of mania or hypomania, discontinuation syndrome, seizures, angle-closure glaucoma, hyponatremia, sexual dysfunction
Postmarketing Irritability, sleep paralysis, hallucinations, suicide attempt, suicidal ideation, rash, urticaria, drug eruption, acute pancreatitis, anosmia, hyposmia
Pharmacology
Levomilnacipran is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI) that potentiates serotonin and norepinephrine neurotransmission in the central nervous system through inhibition of reuptake at their respective transporters, with no significant affinity for other receptors, ion channels, or transporters.
Vilazodone is a selective serotonin reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist thought to enhance serotonergic activity in the CNS through selective inhibition of serotonin reuptake; its exact mechanism in treating major depressive disorder is not fully understood.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fetzima
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (11/12) · Qty limit (12/12)
Viibryd
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (9/12) · Qty limit (1/12)
UnitedHealthcare
Fetzima
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (8/8) · Qty limit (6/8)
Viibryd
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Fetzima
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Viibryd
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Fetzima.
No savings programs available for Viibryd.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FetzimaView full Fetzima profile
ViibrydView full Viibryd profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.